Open Access

Establishment of patient-derived cancer xenografts in immunodeficient NOG mice

  • Authors:
    • Tsuyoshi Chijiwa
    • Kenji Kawai
    • Akira Noguchi
    • Hidemitsu Sato
    • Akimune Hayashi
    • Haruhiko Cho
    • Manabu Shiozawa
    • Takeshi Kishida
    • Soichiro Morinaga
    • Tomoyuki Yokose
    • Makoto Katayama
    • Nobuo Takenaka
    • Hiroshi Suemizu
    • Roppei Yamada
    • Yoshiyasu Nakamura
    • Takashi Ohtsu
    • Yasuo Takano
    • Kohzoh Imai
    • Yohei Miyagi
    • Masato Nakamura
  • View Affiliations

  • Published online on: May 11, 2015
  • Pages: 61-70
  • Copyright: © Chijiwa et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Viable and stable human cancer cell lines and animal models combined with adequate clinical information are essential for future advances in cancer research and patient care. Conventional in vitro cancer cell lines are commonly available; however, they lack detailed information on the patient from which they originate, including disease phenotype and drug sensitivity. Patient-derived xenografts (PDX) with clinical information (so-called ‘cancer xenopatients’) are a promising advance that may accelerate the development of anticancer therapies. We established 61 PDX lines from 116 surgically removed tumor tissues inoculated subcutaneously into NOG mice (53% success rate). PDX lines were established from various types of epithelial tumors and also from sarcomas, including gastrointestinal stromal tumors and Ewing/PNET sarcomas. The metastatic tumors yielded PDX lines more effectively (65%) than the primary tumors (27%, P<0.001). In our PDX models, morphological characteristics, gene expression profiles, and genetic alteration patterns were all well preserved. In eight cases (7%), the transplantable xenografts for several generations were composed of large monotonous nonepithelial cells of human origin, revealed to be Epstein-Barr virus infection-associated lympho­proliferative lesions. Despite this, PDX linked with clinical information offer many advantages for preclinical studies investigating new anticancer drugs. The fast and efficient establishment of individual PDX may also contribute to future personalized anticancer therapies.


Animal models have been used in front-line preclinical studies for predicting efficacy and possible toxicities of anticancer drugs in cancer patients (1,2). Current tumor models used for drug evaluation generally consist of implantation into immunodeficient mice of xenografts generated from well-established human cancer cell lines that have already adapted to in vitro growth. These models have been used extensively for decades for rapid screening of anticancer drug efficacy (3,4).

In recent years, xenografts derived from engrafting fresh surgical specimens directly into immunodeficient mice have enabled the development of more relevant in vivo models for human tumors (5). Such patient-derived xenograft (PDX) models, established by direct transfer of tumor tissue, retain similar morphology, architecture, and molecular signatures as the original cancers and thus should be used for rapid screening of potential therapeutics (6,7). Whereas the conventional xenograft models using cell lines provide only a monoclonal mass of tumor cells, PDX models recapitulate not only interactions from the host microenvironments but also the cancerous heterogeneity including the cancer stem cells (5,6,8). Results from these investigations support the use of direct transfer xenografts as a reliable strategy to anticipate clinical findings, provide direction for optimizing personalized treatment in advanced cancers, and suggest novel treatment opportunities in patients with no other therapeutic options (9). The advantages of PDX models in preserving cancer stem cells and the clinical information of the donor patient (so-called ‘cancer xenopatient’) may allow for accelerated cancer research by simulating the situation in cancer patients more closely (6,7).

However, the establishment of direct xenografts is still technically difficult (1,10,11). Recently, a new immunodeficient animal model, NOD/Shi-scid/IL-2Rγnull (NOG) mice, derived from the NOD/SCID mouse with a common gamma chain, has been introduced. In addition to lacking functional T and B lymphocytes, the NOG mouse has multifunctional defects in natural killer cell activity, macrophage function, complement activity, and dendritic cell function (12). NOG mice were reported to be the most appropriate immunodeficient host animal for direct xenografting of fresh tumor tissue (5).

In the present study, we investigated the efficient establishment of PDX using NOG mice with clinical factors of xenotransplantation. We also discuss herein the application of this newly developed system for not only reliable preclinical studies of new anticancer drugs but also personalized anti-cancer therapies.

Materials and methods

Tumor tissues for transplantation

The 116 surgically removed fresh tumor tissues for transplantation were obtained at Kanagawa Cancer Center (Yokohama, Kanagawa, Japan) and Kawasaki Municipal Hospital (Kawasaki, Kanagawa, Japan) with the patients’ written informed consent for the study. The study was performed in collaboration with Keihin Coastal Area Life Innovation Comprehensive Special Zones for International Competitiveness Development (Japan) from 2011 to 2012. The ethics committees independently approved the study (authorization number: 176 at Kanagawa Cancer Center, 23–410 at Kawasaki Municipal Hospital). The entire list of engrafted tumors with the patient profiles is shown in Table I.

Table I

The entire list of patients from which the engrafted tumors were taken and the fate of the xenografts.

Table I

The entire list of patients from which the engrafted tumors were taken and the fate of the xenografts.

No.AgeGenderOriginal tumor sitePathology Primary/MetastasisTumor typeResult
143MLungAdenosquamous carcinomaBrain metastasisEpithelialEstablished
260MLungAdenocarcinomaBrain metastasisEpithelialEstablished
369MLungAdenocarcinomaBrain metastasisEpithelialFailedc
435FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
551FBreastDuctal carcinomaBrain metastasisEpithelialEstablished
765MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
876FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
960FLungAdenocarcinomaBrain metastasisEpithelialFailedc
1066FLungAdenocarcinomaBrain metastasisEpithelialEstablished
1174FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
1328MBoneEwing/PNETBrain metastasisMesenchymalEstablished
1458MThyroidPapillary carcinomaBrain metastasisEpithelialFailed
1576MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialFailedc
1665FBreastDuctal carcinomaBrain metastasisEpithelialFailed
1769FLarge intestineTubular adenocarcinomaBrain metastasisEpithelialEstablished
1871FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
1974MEsophagusSquamous cell carcinomaBrain metastasisEpithelialEstablished
2068MKidneyRenal cell carcinomaBrain metastasisEpithelialEstablished
2181FLungAdenocarcinomaBrain metastasisEpithelialFailedc
2280MSmall intestineGISTPrimaryMesenchymalFailed
2465FBreastDuctal carcinomaBrain metastasisEpithelialFailed
2551MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
2666MPancreasDuctal carcinomaPrimaryEpithelialFailed
2861MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
3060MStomachGISTPeritoneal metastasisMesenchymalEstablished
3177MStomachTubular adenocarcinomaPeritoneal metastasisEpithelialEstablished
3361FDuodenumTubular adenocarcinomaPrimaryEpithelialFailed
3465FBreastDuctal carcinomaBrain metastasisEpithelialFailed
3564MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
3669FLungSquamous cell carcinomaBrain metastasisEpithelialEstablished
3769FUterus bodyAdenocarcinomaBrain metastasisEpithelialEstablished
38a58FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
3970FLarge intestineTubular adenocarcinomaBrain metastasisEpithelialEstablished
4047MPrimary unknownAdenocarcinomaBrain metastasisEpithelialEstablished
4171FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
4271FUterus bodyAdenocarcinomaBrain metastasisEpithelialFailedc
4355FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
4452MLungSmall cell carcinomaBrain metastasisEpithelialEstablished
4673MLungAdenocarcinomaBrain metastasisEpithelialFailed
4773MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
4855FBreastDuctal carcinomaBrain metastasisEpithelialFailed
4968MStomachTubular adenocarcinomaBrain metastasisEpithelialFailedc
5052MLarge intestineGISTPrimaryMesenchymalFailed
5264MLarge intestineTubular adenocarcinomaBrain metastasisEpithelialFailed
5362FPancreasDuctal carcinomaPrimaryEpithelialEstablished
54b70MPancreasDuctal carcinomaLymph node metastasisEpithelialFailed
55b70MPancreasDuctal carcinomaLymph node metastasisEpithelialEstablished
56b70MPancreasDuctal carcinomaLymph node metastasisEpithelialEstablished
5864MLungLarge cell carcinomaBrain metastasisEpithelialEstablished
5974FPancreasAnaplastic carcinomaPrimaryEpithelialFailed
6071FPancreasDuctal carcinomaPrimaryEpithelialEstablished
6174FPancreasDuctal carcinomaPrimaryEpithelialFailed
6270MKidneyTransitional cell carcinomaBrain metastasisEpithelialFailed
6353FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialFailed
6567MKidneyRenal cell carcinomaBrain metastasisEpithelialEstablished
6682MLungAdenocarcinomaBrain metastasisEpithelialEstablished
6761MKidneyRenal cell carcinomaPeritoneal metastasisEpithelialEstablished
7049MPancreasDuctal carcinomaPrimaryEpithelialFailed
7161FLungAdenocarcinomaBrain metastasisEpithelialEstablished
7270FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialFailedc
7372FLarge intestineGISTPrimaryMesenchymalFailed
7567FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
7760MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
7863FGallbladderPleomorphic carcinomaBrain metastasisEpithelialFailedc
7937FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialFailed
8070MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
8263MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialFailed
8370FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialFailed
8460FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialFailed
8556MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
8658FBreastDuctal carcinomaBrain metastasisEpithelialEstablished
8862MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialFailed
8971MPancreasDuctal carcinomaPrimaryEpithelialEstablished
9065FKidneyRenal cell carcinomaSkin metastasisEpithelialFailed
9151MPancreasDuctal carcinomaPrimaryEpithelialFailed
9251FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialFailed
9375MLungAdenocarcinomaBrain metastasisEpithelialFailed
9480MPancreasDuctal carcinomaPrimaryEpithelialFailed
9577MKidneyRenal cell carcinomaSkin metastasisEpithelialEstablished
9668MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
9763MPancreasDuctal carcinomaPrimaryEpithelialFailed
9861FPancreasDuctal carcinomaPrimaryEpithelialFailed
9967FPancreasDuctal carcinomaPrimaryEpithelialEstablished
10061MLungAdenocarcinomaBrain metastasisEpithelialEstablished
10171MStomachTubular adenocarcinomaBrain metastasisEpithelialEstablished
102a59FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
10363MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
10461FThyroidFollicular carcinomaBrain metastasisEpithelialEstablished
10571MPancreasDuctal carcinomaPrimaryEpithelialEstablished
10646MLarge intestineMucinous adenocarcinomaLiver metastasisEpithelialEstablished
10766MPancreasDuctal carcinomaPrimaryEpithelialEstablished
10880FLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
10965MPancreasDuctal carcinomaPrimaryEpithelialEstablished
11081FThyroidAnaplastic carcinomaPrimaryEpithelialEstablished
11171MPancreasDuctal carcinomaPrimaryEpithelialEstablished
11254FBreastDuctal carcinomaBrain metastasisEpithelialFailed
11362MLarge intestineTubular adenocarcinomaLiver metastasisEpithelialEstablished
11468MLungAdenocarcinomaBrain metastasisEpithelialEstablished
11563MLarge intestineTubular adenocarcinomaBrain metastasisEpithelialEstablished
11678MKidneyRenal cell carcinomaBrain metastasisEpithelialFailed

a Different operations of the same patient,

b independent metastatic lesions of the same operation,

c replaced by lymphoproliferative lesions, M, male; F, female; MPNST, malignant peripheral nerve sheath tumor; GIST, gastrointestinal stromal tumor.


NOG mice, between 6 and 12 weeks of age, were used in this study. The mice were obtained from the Central Institute for Experimental Animals (CIEA; Kanagawa, Japan) (12). All animals were housed in plastic cages (136×208×115 mm) within a vinyl isolator system (1150×500×500 mm) in a pathogen-free state, at a temperature of 22±1°C with 45±10% humidity, and a 12 h light/12 h dark cycle. All experiments involving laboratory animals were performed in accordance with the care and use guidelines of the CIEA, according to our previous studies (1315). These guidelines meet the generally accepted international criteria on humane treatment that spare the animal needless pain and suffering, and require confirmation that the experiments conducted are of actual scientific benefit to humankind.

Procedures for the establishment of PDX models by serial engraftment

Fresh tumor tissues were divided into three pieces under sterile conditions. One piece of each tissue specimen was immediately placed in Dulbecco’s modified minimal essential medium without antibiotics and without fetal bovine serum, and stored at 4°C until engrafting. Another piece was cryopreserved for molecular biological examination, and the last piece was fixed in 4% formaldehyde for histopathological examination. The piece for engraftment was further divided into small pieces (~8–64 mm3) using sterilized surgical scissors. A small incision was made in the leg of each mouse and a transplant needle was inserted until the tip reached the dorsal subcutaneous area. Approximately 10 pieces of tumor tissue were inoculated into the dorsal subcutis via the needle. After the engrafted mass expanded to over quadruple its size, the xenograft tumor was harvested and directly re-transplanted for expansion in later serial generations using the same procedure. After the tumor tissue had been passaged three times or more and histopathological examination confirmed the PDX to be a growing human tumor, we considered the PDX line as ‘established’. The established PDX tissue was divided into small pieces, completely submerged in cryopreservation medium (Cellbanker®1, Zenoaq, Fukushima, Japan), and then stored in liquid nitrogen. The frozen tissues were later thawed and used for experiments including re-transplantation and expansion. Mice that did not develop tumor mass over six months after engraftment were sacrificed as ‘failed’, and this was confirmed histopathologically.

Morphological examination of the primary engrafts and the PDX descendants

For morphological analyses, sample tissues were formalin-fixed, paraffin-embedded (FFPE), sliced into 4-μm sections, and subjected to standard hematoxylin and eosin (H&E) staining or immunohistochemistry (IHC). IHC was performed using the Bond Polymer Refine Detection system (Leica Microsystems, Tokyo, Japan) according to the manufacturer’s instructions. Nuclei were counterstained with hematoxylin. Primary antibodies used for IHC were: monoclonal anti-HLA class 1-A, B, C (Hokudo, Sapporo, Japan), rabbit polyclonal anti-c-kit (Nichirei Biosciences, Tokyo, Japan); monoclonal anti-CD34, clone NU-4A1 (Nichirei Biosciences); monoclonal antileukocyte common antigen, clone PD7/26, 2B11 (CD111, Nichirei Biosciences); HER2 (Hercep Test™, Dako, Japan), monoclonal anti-estrogen receptor (ER), clone 1D5 (Nichirei Biosciences); and monoclonal antiprogesterone receptor (PgR), clone A9621A (Nichirei Biosciences). Chromogenic in situ hybridization (ISH) for Epstein-Barr virus (EBV)-encoded RNA (EBER) was performed using the EBER 1 DNP probe (Ventana/Roche, Tuscon, AZ, USA) and the ISH iView blue plus detection kit (Ventana/Roche) according to the provider’s instructions.

Genetic examination of xenograft tumors in NOG mice

The exon 11 deletion mutation in the KIT gene in the 3rd generation xenograft of the gastrointestinal stromal tumor (GIST) was investigated as previously described (16). Briefly, DNA was extracted from the FFPE thin sections of the xenograft tumor and amplified by polymerase chain reaction (PCR) with primers: 5′-gactgagacaataattattaaaag-3′ (forward) and 5′-acccaaaaaggtgacatggaaagc-3′ (reverse). PCR products were then directly sequenced using the PCR primers and the Sanger’s method with Genetic Analyzer 3100 (Applied Biosystems/Hitachi, Japan). For EWS-FLI1 fusion mRNA detection, total RNA was extracted from the 3rd generation xenograft of the Ewing sarcoma/primitive neuroectodermal tumor (PNET), reverse transcribed to cDNA, and PCR-amplified with primers: EWS-exon 8 (5′-tcctacagccaagctccaagtc-3′) and the FLI1 exon 9 (5′-gtgatacagctggcgttggc-3′). The obtained product was directly sequenced as described for the KIT analysis.

Statistical analysis

Statistical comparisons of data sets were performed by a two-sample t-test. The Chi-square test or the two-sided Fisher’s probability exact test was applied for comparisons between group frequencies. These analyses were performed using JMP version 11 software (SAS Institute Inc., Cary, NC, USA). P-values of <0.05 were considered significant.


Efficacy of PDX line establishment in NOG mice

In total, 116 surgically removed tumor tissues were engrafted in NOG mice (Tables I and II). The group of patients who provided tumors for this study comprised 63 men and 53 women, with a mean age of 63 years. Thirty-seven tumors were obtained from primary sites and 79 tumors were from metastases. Ninety-eight tumors were epithelial (carcinomas) and 18 tumors were nonepithelial (sarcomas). Tumor specimens were engrafted on the day of surgery or 1–6 days after the surgical removal (owing to sample transport and public holidays). The primary organ site of the transplant together with the difference between the primary tumor or metastasis and the fate (established or failed) are summarized in Table III.

Table II

Summary of the engrafted tumors and the fate of xenografts.

Table II

Summary of the engrafted tumors and the fate of xenografts.

Engrafted tumor informationEstablishedFailed (LPL)Total

Organ siteTypePrimaryMetastasisPrimaryMetastasisPrimaryMetastasis
 StomachEpithelial0201 (1)03
 Small intestineEpithelial001010
 Large intestineEpithelial025010 (2)035
Other digestive
 GallbladderEpithelial0001 (1)01
 LungEpithelial01005 (3)015
Breast and female genital
 UterusEpithelial0101 (1)02
 Primary unknownEpithelial010001

[i] LPL, lymphoproliferative lesions.

Table III

Comparison of the establishment rate of xenograft lines.

Table III

Comparison of the establishment rate of xenograft lines.

Original tumor sites0.29a
 Other digestive10102050
 Breast and female36933
Tumor type<0.001b
Tumor site<0.001b
Time to engraftmentc0.49b

a Chi-square test,

b two-sided Fisher’s probability exact test,

c engraftment on the day of surgery or the next day was considered ‘early’, and engraftment after 2 days was considered as ‘delayed’.

PDX lines were considered established when they were passaged three times or more and histopathological examination confirmed their human origin and their morphological similarity to the corresponding engrafted tumor. Of the 116 tumors engrafted, 61 were established as PDX lines, a success rate of 53%. On comparing the established cases with the failed cases, no significant differences were observed in age or gender. The average age of patients in established cases was 64 years, compared with 63 years in the failed cases and there was no statistically significant difference (P=0.53, t-test). In the established cases, 38 cases were from male patients (60%) and 23 were from female patients (43%) cases and there was also no statistically significant difference (P=0.09, Fisher’s probability exact test). High establishment rates of PDX lines were observed in tumors of the respiratory system (67%), gastrointestinal tumors (58%), and urological tumors (57%). None of the primary prostatic tumors or brain tumors yielded PDX lines in multiple trials.

The establishment rate among the primary organ sites of engrafts was different; however, there was no statistical significance (P=0.29, Chi-square test). Fifty-eight PDX lines of carcinomas (59%) and three of sarcomas (17%) were established, and the establishment rate was significantly higher for carcinomas (P<0.001, Fisher’s probability exact test). Metastatic tumors yielded PDX lines more effectively than tumors from primary sites (65% and 27%, respectively; P<0.001, Fisher’s probability exact test). Tumors engrafted into NOG mice two or more days after surgical removal showed a higher establishment rate (61%) than those engrafted on the day of surgery or the next day (51%), but there was no statistically significant difference (P=0.49, Fisher’s probability exact test).

Preservation of the original tumor characteristics in the PDX of NOG mice

The morphological characteristics of the transplanted tumors, as examined by H&E-staining, were well maintained in the corresponding xenograft tumors both cellularly and structurally. One representative case of the PDX line derived from a brain metastasis of an adenosquamous carcinoma of the lung is presented in Fig. 1. The primary tumor of the lung consisted of an adenocarcinoma component and a less abundant squamous carcinoma component, and the transitional pattern between them was rare (Fig. 1A and B). In contrast, the brain metastasis tumor that was engrafted in NOG mice showed a histological structure of an admixture of adenocarcinoma and squamous carcinoma components, and the tumor characteristics were well preserved in the xenograft tumors through the 1st to the 5th generations (Fig. 1C and D). All of the components of the PDX tumor, except for the interstitium, were confirmed as having human origin by IHC for HLA class I (Fig. 1E). Similarly, a brain metastasis of a poorly differentiated adenocarcinoma of the lung was established as a PDX tumor of a poorly differentiated adenocarcinoma (Fig. 1F and G), whereas a liver metastasis of a moderately differentiated adenocarcinoma of the colon with a cribriform pattern was established as a PDX tumor with a similar histology, indicating that differentiation capacity was generally preserved (Fig. 1H and I).

Protein expression, as examined by IHC, was also well maintained in PDX tumors. Only one PDX line was successfully established from 10 trials of GIST engraftment (Table I). The established line was derived from a recurrent metastasis after imatinib methylate treatment. The 3rd generation xenograft was examined and revealed to be strongly positive for c-kit (a proto-oncogene) and CD34 (Fig. 2A–D). A PDX line established from a brain metastasis of a HER2-positive breast cancer showed strong membranous positivity (3+) for HER2, and weak dispersed positivity for ER and PgR, and therefore shared the same characteristics as the engrafted tumor (Fig. 2E–I).

As expected, genetic alterations were conserved in the PDX tumors of NOG mice. The engrafted GIST tumor contained a 51-nucleotide deletion in exon 11 of KIT (r.1667_1717 del/p. Q556_D572 del) and DNA extracted from the 3rd generation xenograft was found to contain an identical mutation (Fig. 3A). Furthermore, the Ewing/PNET sarcoma xenograft tumor established from a brain metastasis contained the EWS-FLI1 fusion mRNA just as the original engraft (Fig. 3B and C).

Lymphoproliferative lesion (LPL) in NOG mice

In eight cases (7% of all engraftments), transplantable xenograft tumors composed of large monotonous nonepithelial cells were observed whose morphology differed from that of the original tumor (Fig. 4A). This phenomenon was observed only in epithelial tumor engraftments (Tables I and II). The monotonous cells were HLA class I positive, demonstrating their human origin, and were also positive for leukocyte common antigen (CD111) by IHC and EBER by ISH, indicating the possibility that they were EBV infection-associated LPLs (Fig. 4B–D).


In this study, we aimed to establish a PDX line in NOG mice that preserved the original characteristics of the engrafted tumor. In a previous PDX trial in NOG mice, which included more than 300 surgically removed tumors, the establishment rate of the xenograft line was 16% (41 of 259 engrafts) for primary tumors, 31% (5 of 16 engrafts) for distant metastasis sites, and 16% (8 of 51 engrafts) for lymph node metastases (5). In this study, we achieved higher establishment rates both for primary tumors (27%) and metastatic tumors (65%). However, the constitution of the tumors used for PDX and those in the primary organ site, the ratios of primary tumors to metastatic tumors, and the numbers of each case all differed between our study and the previous study, making comparisons difficult. For example, the previous study in NOG mice used 57 primary breast cancers and obtained only three PDX lines (5%), whereas primary tumors of the breast were not included in our study (5). In fact, the establishment rate may depend on the organ site from which the engraft is taken.

Colorectal tumors showed relatively higher establishment rates than tumors from other sites in nude or SCID mice (10,11); this was also the case in the previous NOG study (17/48 engraftments, 35%) (5). In the present study, establishment rates were found to differ between sites (e.g., 58% for gastrointestinal tumors compared with 14% for urological tumors) but this difference was not statistically significant. The establishment rates of metastatic tumors were significantly higher than those of primary tumors, a finding that was consistent with previous studies (5,17,18). In our study, carcinomas showed a significantly higher establishment rate (59%) than nonepithelial tumors (17%); however, a limited number of nonepithelial tumors were tested and a larger sample size would be needed to confirm this difference.

In the present study, only subcutaneous transplantations were performed. The transplantation site has been reported to have an influence on xenograft growth (5,1921). Considering what is known about tumor cells and microenvironmental biology, heterotopic subcutaneous tumor models seem to have some shortcomings compared with orthotopic transplantation, especially in the establishment rate and preservation of the original tumor characteristics (21). However, our subcutaneous models revealed well-preserved characteristics of the original engrafts in morphology, protein expression and gene alterations. Although further studies are needed to clarify whether this was because of the highly immunodeficient nature of NOG mice, the establishment of PDX using manageable subcutaneous transplantations is convenient when compared with skillful orthotopic transplantation.

Unexpectedly, in the present study, we experienced no significant difference in the establishment rate of PDX lines between the tumors engrafted early (on the day of surgery or the next day) and the tumors engrafted after 2 days. To the best of our knowledge, no previous studies have investigated this issue. One could speculate that the so-called cancer stem cells responsible for tumorigenicity in mice might be resistance to the severe stress induced by removal from the patients. Although further investigation is needed, this information might help oncology researchers to improve and simplify PDX line establishment, particularly in light of our findings that subcutaneous transplantation is not inferior to orthotopic transplantation with regard to preserving the original engraft characteristics.

The high occurrence of LPL was the most problematic aspect of the establishment of NOG mice-PDX, which arose because of the severely immunodeficient nature of the animal model. In eight cases (7% of all engraftments), the engrafted tumors were replaced by LPL until the 3rd generation of xenografts. The LPLs were demonstrated to be EBV infection-associated, as has been previously reported (20,22,23). Fujii and colleagues also reported that EBV-infected B cells originating from the donor were distributed systemically within the NOG mouse (23). LPLs were transplantable, and difficult to distinguish from the proper xenografts in terms of gross appearance. It is therefore important that histology of xenografts is checked before transplantation into new mice. However, the frequency of LPLs is acceptable when considering the merits of NOG mice. Replacement of the engrafted tumors by LPL accounted for 15% of the failed cases in PDX line establishment, indicating that the major cause of failed cases is therefore likely to be the nature of the xenografts.

Owing to progression in the field of oncology, the demand for relevant human tumor models is increasing. In vivo models play a vital role in the extrapolation of data to human patients, especially in the development of anticancer agents. Evidence that both tumor differentiation and tumor structure were highly conserved between the original surgical specimen and the PDX tumor confirms the suitability of our mouse model for the study of tumor biology. Applications of this model, not only for more common tumors, but also for uncommon tumors, such as sarcomas or pediatric tumors, will provide researchers with reliable comparative preclinical data that may contribute to the development of novel cancer therapies. The rapid and efficient establishment of PDX linking with clinical information may lead in the future to the development of personalized anticancer therapies by simulating various treatments in individual PDX mice, so-called cancer xenopatients.


The authors thank Ms. Aki Namiki, Miyuki Kon, Takayo Shimamura, and Manami Ino at the Kanagawa Cancer Center for their assistance in tissue preparation and obtaining informed consent from patients involved in the study. This work was partly supported by JSPS Grant-in-Aid for Scientific Research (C), numbers 25430098 and 26430097.



Morton CL and Houghton PJ: Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2:247–250. 2007. View Article : Google Scholar : PubMed/NCBI


Jin K, Li G, Cui B, Zhang J, Lan H, Han N, Xie B, Cao F, He K, Wang H, et al: Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS One. 6:e283842011. View Article : Google Scholar : PubMed/NCBI


Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, et al: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 84:1424–1431. 2001. View Article : Google Scholar : PubMed/NCBI


Sausville EA, Burger AM, Becher OJ and Holland EC: Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66:3351–3354. 2006. View Article : Google Scholar : PubMed/NCBI


Fujii E, Suzuki M, Matsubara K, Watanabe M, Chen YJ, Adachi K, Ohnishi Y, Tanigawa M, Tsuchiya M and Tamaoki N: Establishment and characterization of in vivo human tumor models in the NOD/SCID/gamma(c)(null) mouse. Pathol Int. 58:559–567. 2008. View Article : Google Scholar : PubMed/NCBI


Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, et al: A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1:508–523. 2011. View Article : Google Scholar


Galimi F, Torti D, Sassi F, Isella C, Corà D, Gastaldi S, Ribero D, Muratore A, Massucco P, Siatis D, et al: Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: Response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res. 17:3146–3156. 2011. View Article : Google Scholar : PubMed/NCBI


Kobayashi S, Yamada-Okabe H, Suzuki M, Natori O, Kato A, Matsubara K, Jau Chen Y, Yamazaki M, Funahashi S, Yoshida K, et al: LGR5-positive colon cancer stem cells inter-convert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells. 30:2631–2644. 2012. View Article : Google Scholar : PubMed/NCBI


Scott CL, Becker MA, Haluska P and Samimi G: Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol. 3:2952013. View Article : Google Scholar : PubMed/NCBI


Tokunaga T, Nakamura M, Oshika Y, Ohnishi Y and Ueyama Y: Is xenotransplantability of human colon cancers in SCID mice affected by angiogenic factors? J Natl Cancer Inst. 90:400–401. 1998. View Article : Google Scholar : PubMed/NCBI


Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N, Validire P, et al: Establishment of human colon cancer cell lines from fresh tumors versus xenografts: Comparison of success rate and cell line features. Cancer Res. 67:398–407. 2007. View Article : Google Scholar : PubMed/NCBI


Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, et al: NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood. 100:3175–3182. 2002. View Article : Google Scholar : PubMed/NCBI


Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N and Nakamura M: Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice. Int J Oncol. 31:741–751. 2007.PubMed/NCBI


Chijiwa T, Abe Y, Ikoma N, Yamazaki H, Tsukamoto H, Suemizu H, Kawai K, Wakui M, Nishime C, Matsumoto H, et al: Thrombospondin 2 inhibits metastasis of human malignant melanoma through microenvironment-modification in NOD/SCID/gammaCnull (NOG) mice. Int J Oncol. 34:5–13. 2009.


Kubo A, Ohmura M, Wakui M, Harada T, Kajihara S, Ogawa K, Suemizu H, Nakamura M, Setou M and Suematsu M: Semi-quantitative analyses of metabolic systems of human colon cancer metastatic xenografts in livers of superimmunodeficient NOG mice. Anal Bioanal Chem. 400:1895–1904. 2011. View Article : Google Scholar : PubMed/NCBI


Cho H, Watanabe T, Aoyama T, Hayashi T, Yamada T, Ogata T, Yoshikawa T, Tsuburaya A, Sekiguchi H, Nakamura Y, et al: Small bud of probable gastrointestinal stromal tumor within a laparoscopically-resected gastric schwannoma. Int J Clin Oncol. 17:294–298. 2012. View Article : Google Scholar


Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T and Ogawa O: Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res. 65:9611–9616. 2005. View Article : Google Scholar : PubMed/NCBI


Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, et al: A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 13:3989–3998. 2007. View Article : Google Scholar : PubMed/NCBI


Mueller BM and Reisfeld RA: Potential of the scid mouse as a host for human tumors. Cancer Metastasis Rev. 10:193–200. 1991. View Article : Google Scholar : PubMed/NCBI


Bankert RB, Hess SD and Egilmez NK: SCID mouse models to study human cancer pathogenesis and approaches to therapy: Potential, limitations, and future directions. Front Biosci. 7:c44–c62. 2002. View Article : Google Scholar : PubMed/NCBI


Bibby MC: Orthotopic models of cancer for preclinical drug evaluation: Advantages and disadvantages. Eur J Cancer. 40:852–857. 2004. View Article : Google Scholar : PubMed/NCBI


Itoh T, Shiota M, Takanashi M, Hojo I, Satoh H, Matsuzawa A, Moriyama T, Watanabe T, Hirai K and Mori S: Engraftment of human non-Hodgkin lymphomas in mice with severe combined immunodeficiency. Cancer. 72:2686–2694. 1993. View Article : Google Scholar : PubMed/NCBI


Fujii E, Kato A, Chen YJ, Matsubara K, Ohnishi Y and Suzuki M: Characterization of EBV-related lymphoproliferative lesions arising in donor lymphocytes of transplanted human tumor tissues in the NOG mouse. Exp Anim. 63:289–296. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

Volume 47 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
Spandidos Publications style
Chijiwa T, Kawai K, Noguchi A, Sato H, Hayashi A, Cho H, Shiozawa M, Kishida T, Morinaga S, Yokose T, Yokose T, et al: Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. Int J Oncol 47: 61-70, 2015
Chijiwa, T., Kawai, K., Noguchi, A., Sato, H., Hayashi, A., Cho, H. ... Nakamura, M. (2015). Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. International Journal of Oncology, 47, 61-70.
Chijiwa, T., Kawai, K., Noguchi, A., Sato, H., Hayashi, A., Cho, H., Shiozawa, M., Kishida, T., Morinaga, S., Yokose, T., Katayama, M., Takenaka, N., Suemizu, H., Yamada, R., Nakamura, Y., Ohtsu, T., Takano, Y., Imai, K., Miyagi, Y., Nakamura, M."Establishment of patient-derived cancer xenografts in immunodeficient NOG mice". International Journal of Oncology 47.1 (2015): 61-70.
Chijiwa, T., Kawai, K., Noguchi, A., Sato, H., Hayashi, A., Cho, H., Shiozawa, M., Kishida, T., Morinaga, S., Yokose, T., Katayama, M., Takenaka, N., Suemizu, H., Yamada, R., Nakamura, Y., Ohtsu, T., Takano, Y., Imai, K., Miyagi, Y., Nakamura, M."Establishment of patient-derived cancer xenografts in immunodeficient NOG mice". International Journal of Oncology 47, no. 1 (2015): 61-70.